Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q1 2021 · 10-Q
Revenue$124.93M$124.93M+24.4% vs Q1 2020 Net Income-$167.25M-$167.25MN/M vs Q1 2020 EPS Diluted-$2.10-$2.10N/M vs Q1 2020 Operating Income-$151,865,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
Free Cash Flowderived-$201,520,000N/M Margins · derivedOperating margin-121.6%−4.1 pt vs Q1 2020
Net margin-133.9%−116.5 pt vs Q1 2020
ended Mar 31, 2021 · filed May 5, 2021 · 35 d after period end